FENC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FENC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Fennec Pharmaceuticals has the Financial Strength Rank of 5.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Fennec Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 was 13.27. Fennec Pharmaceuticals's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.31. As of today, Fennec Pharmaceuticals's Altman Z-Score is -0.46.
For the Biotechnology subindustry, Fennec Pharmaceuticals's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Financial Strength distribution charts can be found below:
* The bar in red indicates where Fennec Pharmaceuticals's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Fennec Pharmaceuticals's Interest Expense for the months ended in Mar. 2024 was $-1.03 Mil. Its Operating Income for the months ended in Mar. 2024 was $13.72 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $31.35 Mil.
Fennec Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is
Interest Coverage | = | -1 | * | Operating Income (Q: Mar. 2024 ) | / | Interest Expense (Q: Mar. 2024 ) |
= | -1 | * | 13.723 | / | -1.034 | |
= | 13.27 |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Fennec Pharmaceuticals's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Mar. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (0.017 | + | 31.349) | / | 101.508 | |
= | 0.31 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Fennec Pharmaceuticals has a Z-score of -0.46, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
Warning Sign:
Altman Z-score of -0.46 is in distress zone. This implies bankruptcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fennec Pharmaceuticals (NAS:FENC) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Fennec Pharmaceuticals has the Financial Strength Rank of 5.
Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Andrade | officer: Chief Financial Officer | C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
Rosty Raykov | director, officer: Chief Executive Officer | C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
Chris A Rallis | director | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Adrian Haigh | director | 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27 |
Marco Maria Brughera | director | VIALE STEFINI 14, MILANO L6 00000 |
Khalid Islam | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Shubh Goel | officer: Chief Commercial Officer | 1100 MAXWELL, #522, HOBOKEN NJ 07030 |
Southpoint Capital Advisors Lp | 10 percent owner | 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036 |
Spa Essetifin | 10 percent owner | VIA SUDAFRICA 20, ROME L6 00144 |
Jodi A Cook | director | PO BOX 816, NEWTOWN PA 08540 |
Manchester Management Pr, Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Francesca Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Paolo Cavazza | 10 percent owner | VIA TESSERETE, 10, LUGANO V8 V8 |
Silvia Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Enrico Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
From GuruFocus
By sperokesalga sperokesalga • 03-31-2023
By sperokesalga sperokesalga • 05-08-2023
By Stock market mentor Stock market mentor • 01-31-2023
By PurpleRose PurpleRose • 07-11-2022
By GlobeNewswire GlobeNewswire • 06-06-2023
By GuruFocusNews GuruFocusNews • 06-11-2022
By Marketwired • 08-03-2023
By Marketwired • 09-07-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
By sperokesalga sperokesalga • 06-12-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.